merged_insulin-prices-federal-clinics-340b.txt
<question_number>1</question_number>
<answer>77%</answer>
<question_number>2</question_number>
<answer>N/A</answer>
<question_number>3</question_number>
<answer>Medicare drug price negotiation</answer>
<question_number>4</question_number>
<answer>20%</answer>
<question_number>5</question_number>
<answer>helping patients find housing</answer>
<question_number>6</question_number>
<answer>N/A</answer>
<question_number>7</question_number>
<answer>requirement for manufacturers to pay state Medicaid plans for each use of drugs whose prices increase above inflation</answer>
<question_number>8</question_number>
<answer>N/A</answer>
<question_number>9</question_number>
<answer>1900%</answer>
<question_number>10</question_number>
<answer>diabetes complications</answer>
<question_number>11</question_number>
<answer>N/A</answer>
<question_number>12</question_number>
<answer>N/A</answer>
<question_number>13</question_number>
<answer>$490</answer>
<question_number>14</question_number>
<answer>Health Resources and Services Administration</answer>
<question_number>15</question_number>
<answer>23%</answer>
<question_number>16</question_number>
<answer>8</answer>
<question_number>17</question_number>
<answer>Byetta</answer>
<question_number>18</question_number>
<answer>2021</answer>
<question_number>19</question_number>
<answer>N/A</answer>
<question_number>20</question_number>
<answer>insulin</answer>